REG - Destiny Pharma PLC - Appointment of Corporate Broker

Destiny PharmaAnnouncement

23/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221123:nRSW2533Ha&default-theme=true

RNS Number : 2533H  Destiny Pharma PLC  23 November 2022

 

23 November 2022

 

Destiny Pharma plc

 

("Destiny Pharma" or "the Company")

 

Appointment of Corporate Broker

 

Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused
on the development of novel medicines to prevent life threatening infections,
is pleased to announce the appointment of Shore Capital as joint corporate
broker, to work alongside the Company's Nominated Adviser and existing
corporate broker finnCap Ltd, with immediate effect.

 

 

For further information, please contact:

 

 Destiny Pharma                                                                        +44 (0)1273 704 440
 plc

                                                                                     pressoffice@destinypharma.com
 Neil Clark, CEO

 Shaun Claydon, CFO

 finnCap Ltd (Nominated Adviser and Joint Broker)                                      +44 (0) 207 220 0500

 Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

 Alice Lane / Nigel Birks / Harriet Ward, ECM

 Shore Capital (Joint Broker)                                                          +44 (0) 20 7408 4090

 Daniel Bush / James Thomas / Lucy Bowden

 Optimum Strategic Communications                                                      +44 (0) 208 078 4357

 Mary Clark / Nick Bastin / Manel Mateus                                               DestinyPharma@optimumcomms.com

 MC Services AG                                                                        +49-211-529252-12

 Anne Hennecke / Andreas Burckhardt

 Stern IR - US                                                                         +1-212-362-1200

 Janhavi Mohite                                                                        Janhavi.Mohite@sternir.com

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has recently completed a positive Phase 2b clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA.
It is also co-developing SporCov, a novel, biotherapeutic product for the
prevention of COVID-19 and other viral respiratory infections and has earlier
grant funded XF research projects.

For further information on the company, please
visit https://www.destinypharma.com (https://www.destinypharma.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPEALFAAFLAFFA